Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-008385.pdf
0001415889-22-008385.rtf
0001415889-22-008385.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-084972.pdf
0001104659-22-084972.rtf
0001104659-22-084972.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-22-011648.pdf
0001558370-22-011648.rtf
0001558370-22-011648.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
S-8

Securities offered to employees pursuant to employee benefit plans

 View HTML
0001104659-22-085262.pdf
0001104659-22-085262.rtf
0001104659-22-085262.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-076292.pdf
0001104659-22-076292.rtf
0001104659-22-076292.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-007128.pdf
0001415889-22-007128.rtf
0001415889-22-007128.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-007129.pdf
0001415889-22-007129.rtf
0001415889-22-007129.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-007133.pdf
0001415889-22-007133.rtf
0001415889-22-007133.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-007132.pdf
0001415889-22-007132.rtf
0001415889-22-007132.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-007130.pdf
0001415889-22-007130.rtf
0001415889-22-007130.xls